M&G have announced that it has invested in Osler Diagnostics, a medical diagnostic company aiming to transform global healthcare by providing lab-quality diagnostic testing to anyone, anywhere, at any time.
The investment will support the company in advancing its breakthrough Osler Origin product through regulatory activities, and towards market launch. The Osler Origin is a portable diagnostic capable of performing a wide range of testing, with high-performance, in a rapid, low-cost, and easy-to-use manner. It has the potential to offer a wide portfolio of high-performance diagnostic tests, into all major healthcare settings, globally.
The investment has been made by M&G’s Catalyst strategy, which invests in innovative, privately-owned global businesses working to create a more sustainable world. Osler was formed out of the University of Oxford in 2017 and this investment marks Catalyst’s latest investment in UK academic innovation and impact, following previous investments in Vaccitech and Oxford Nanopore Technologies, among others.
Niranjan Sirdeshpande, Global Head of Investments, Catalyst, comments: “The Osler Origin has the potential to transform the speed and accuracy of diagnostics so patients receive much-needed medical interventions in a timely manner. Through our investment in Osler and wider investments Catalyst has made into academic spin outs, we are seeking to back innovative companies that will contribute towards creating a more sustainable world.”
Connor Campbell, Co-Founder and Chief Executive of Osler Diagnostics, says: “The Osler Origin platform has the potential to transform healthcare by enabling anyone, anywhere, to access, understand, and act on their healthcare information. This new investment allows us to advance the Osler Origin towards market, and to realise our vision.”